Forest Ends Phenomix Partnership, But Says Its Many Deals Are Bearing Fruit
This article was originally published in The Pink Sheet Daily
Executive Summary
In same-day earnings call, the specialty pharma company reported year-end fiscal 2010 sales of $4.2 billion, up 6.9 percent.
You may also be interested in...
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.
In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs
Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.
Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes
DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.